View Financial HealthPanacea Life Sciences Holdings 配当と自社株買い配当金 基準チェック /06Panacea Life Sciences Holdings配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.お知らせ • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0お知らせ • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.お知らせ • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.お知らせ • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.お知らせ • Jan 24Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.お知らせ • Jul 24Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of DirectorsPanacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position.お知らせ • Jul 15Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVIDPanacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.お知らせ • Aug 18Exactus, Inc. announced delayed 10-Q filingOn 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: PLSHの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PLSHの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Panacea Life Sciences Holdings 配当利回り対市場PLSH 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PLSH)n/a市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (PLSH) (最長3年)n/a注目すべき配当: PLSHは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PLSHは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PLSHの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PLSHが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 04:31終値2026/08/07 00:00収益2024/03/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Panacea Life Sciences Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 16Panacea Life Sciences Holdings, Inc. Files Form 15Panacea Life Sciences Holdings, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share.
お知らせ • Jun 13Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.Panacea Life Sciences Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $6 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 30,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0
お知らせ • Oct 07Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023. Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) completed the acquisition of N7 Enterprises, Inc. on October 5, 2023.
お知らせ • Aug 17Panacea Life Sciences Holdings, Inc. announced delayed 10-Q filingOn 08/15/2023, Panacea Life Sciences Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 03Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million on August 2, 2023. The consideration includes $2 million in cash, $3 million worth of Panacea Stock and additional earn-out components consisting of $15 million of Panacea Stock. The transaction is subject to Panacea’s satisfactory completion of due diligence of SSH and Halucenex, receipt of applicable corporate approvals of the transaction by the board of directors and shareholders, the execution of the definitive agreement and any ancillary agreements, the receipt of any regulatory approvals and third-party consents, financing (debt or equity) arrangements for Panacea’s $2 million cash payment and projected cash flow deficits from the transaction, on terms satisfactory to Panacea, certain key management personnel and employees entering into consultancy and restrictive covenant agreements with Panacea on terms agreed to with Panacea, confirmation that SSH and Halucenex own their respective intellectual property or licenses and have all required approval for all business operations and ownership including legal and regulatory approvals, by all regulatory agencies, there being no material adverse change in the business, results of operations, prospects, condition (financial or otherwise) or assets of SSH and Halucenex. Paradox Capital Partners, LLC acted as advisor to Panacea.
お知らせ • Jul 12Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) agreed to acquire Nitro Kava & Kratom from Gary Wilder, Lizard Juice, LLC, N7 Enterprises, Inc. and New Age Distribution Corp on July 3, 2023. The purchase price for the acquisition consists of no cash and the agreement to issue approximately 85,000 shares of a new class of convertible preferred stock, which is convertible into approximately 8.5 million shares of common stock to Nitro Kava & Kratom. The acquisition includes eight retail locations in the Tampa, Florida area, offering Kava, Kratom, VAPE and CBD products and beverages operating as Nitro Kava & Kratom, including inventory, equipment and recipes, distribution facilities and a warehouse located in Largo, Florida. Nitro Kava & Kratom generated $2.9 million of annual revenues (unaudited) for the fiscal year ended December 31, 2022. Closing of the acquisition is subject to satisfaction of customary terms and conditions for a transaction of this kind, including delivery by sellers of audited financial statements for the prior two completed fiscal years for the acquisition. The transaction is subject to N7 Enterprises shareholders.
お知らせ • Jan 24Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million.Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a letter of intent to acquire N7 Enterprises, Inc. for $2.7 million on January 19, 2023. Pursuant to the terms of the letter of intent, Panacea would acquire all of the outstanding membership interests of N7 Enterprises in consideration for the issuance of common shares of the Company to the existing shareholders of N7 Enterprises. For its two business segments, N7 Enterprises showed $4.1 million in revenue for the 2022 fiscal year. Pursuant to the Letter of Intent, the Company and N7 Enterprises agreed to negotiate and enter into a definite merger and share exchange purchase agreement to effect the acquisition of N7 Enterprises through the Merger. Under the Letter of Intent, and subject to the negotiation of the Definitive Agreement, at the time of the Merger we would issue to N7 Enterprises’ stockholders 22.2 million shares of Panacea common stock. The deal is expected to close on around February 28, 2023.
お知らせ • Jul 24Panacea Life Sciences Holdings, Inc. Announces Resignation of Janice Nerger to Its Board of DirectorsPanacea Life Sciences Holdings, Inc. announced that on July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors, effective immediately. Dr. Nerger has accepted the position of interim provost at Colorado State University and has decided to focus on her new position.
お知らせ • Jul 15Panacea Life Sciences Announces Launch of CBDA Oil Drops as Potential Complementary Treatment for Long COVIDPanacea Life Sciences Holdings, Inc. announced the addition of CBDA Oil Drops, which is thought to provide potential advantages as a preventative agent against SARS-CoV-2 as well as the effects of Long COVID. In January 2022, the results of a study led by Oregon State University researcher Richard van Breemen were published in the Journal of Natural Products and concluded that CBDA and CBGA can bind to the SARS-CoV-2 spike protein, blocking the virus's ability to infect people. Much more research is necessary to make definitive claims, but as a compliment to vaccines, CBD and CBDA may provide effective prevention and treatment of SARS-CoV-2. Panacea's CBDA Oil Drops tincture, which contains 50mg of CBDA per serving as well as immunity boosting Zinc and Vitamin D, remains one of few products of its kind to be available on the market.
お知らせ • Aug 18Exactus, Inc. announced delayed 10-Q filingOn 08/17/2021, Exactus, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.